World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
37904
World Ranking
8884
National Ranking
271

Carle Paul publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Carle Paul sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 531 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Carle Paul D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Carle Paul sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Carle Paul is affiliated with the Federal University of Toulouse Midi-Pyrénées in France. Their research primarily focuses on medicine, with significant contributions to immunology and microbiology. Within these broader fields, they have specialized expertise in immunology, dermatology, immunology and allergy, rheumatology, and physiology.

The main topics addressed in their work include dermatology and skin diseases, psoriasis treatment and pathogenesis, allergic rhinitis and sensitization, urticaria and related conditions, autoimmune bullous skin diseases, health systems and economic evaluations concerning quality of life, as well as asthma and respiratory diseases.

Carle Paul has published frequently in the following venues:

  • Journal of the European Academy of Dermatology and Venereology
  • Annales de Dermatologie et de Vénéréologie - FMC
  • Journal of the American Academy of Dermatology
  • British Journal of Dermatology
  • SKIN The Journal of Cutaneous Medicine

Their recent scholarly articles include:

  • ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children, 2020, Journal of the European Academy of Dermatology and Venereology
  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis, 2021, New England Journal of Medicine
  • Bimekizumab versus Secukinumab in Plaque Psoriasis, 2021, New England Journal of Medicine
  • Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis, 2020, New England Journal of Medicine
  • Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials, 2023, The Lancet

Carle Paul regularly collaborates with a number of researchers, frequently co-authoring publications with M.-A. Richard, C. Bulaï Livideanu, M. Tauber, D. Jullien, and P. Joly.

Best Publications

  • Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer

    E. E. Calle;C. W. Heath;R. J. Coates;J. M. Liff

  • Breast cancer and hormonal contraceptives : collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies

    E. E. Calle;C. W. Heath;H. L. Miracle-McMahill;R. J. Coates

  • Alcohol, tobacco and breast cancer - Collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease

    N Hamajima;K Hirose;K Tajima;T Rohan

  • Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies

    N. Hamajima;K. Hirose;K. Tajima;T. Rohan

  • Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Mark Lebwohl;Bruce Strober;Alan Menter;Kenneth Gordon

  • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Christopher E M Griffiths;Kristian Reich;Mark Lebwohl;Peter van de Kerkhof

  • First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.

    Pascal Joly;Maud Maho-Vaillant;Catherine Prost-Squarcioni;Vivien Hebert

  • Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence

    N. Hamajima;K. Hirose;K. Tajima;T. Rohan

  • Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

    Mark G. Lebwohl;Hervé Bachelez;Jonathan Barker;Giampiero Girolomoni

  • Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children

    Ulrich Wahn;Jan D. Bos;Mark Goodfield;Ruggero Caputo

  • Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

    C Paul;J Cather;M Gooderham;Y Poulin

  • European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC

    A Nast;P Gisondi;A D Ormerod;P Saiag

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

    Carle F. Paul;Vincent C. Ho;Claire McGeown;Enno Christophers

  • Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug

    Alexander Kapp;Kim Papp;Ann Bingham;Regina Fölster-Holst

  • Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review.

    C. Horreau;C. Pouplard;E. Brenaut;T. Barnetche

  • Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis

    C. Paul;P. Wolkenstein;H. Adle;J. Wechsler

  • Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

    Phoebe Rich;B. Sigurgeirsson;D. Thaci;J. P. Ortonne

  • Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review

    E. Archier;S. Devaux;E. Castela;A. Gallini

  • Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis

    Felix M Arellano;Charles E Wentworth;Alejandro Arana;Carlos Fernández

Frequent Co-Authors

Pascal Joly
Pascal Joly University of Rouen
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Kim Papp
Kim Papp Probity Medical Research
Olivier Hermine
Olivier Hermine Necker-Enfants Malades Hospital
Giampiero Girolomoni
Giampiero Girolomoni University of Verona
Kristian Reich
Kristian Reich University of Göttingen
Guy Serre
Guy Serre Federal University of Toulouse Midi-Pyrénées
Olivier Chosidow
Olivier Chosidow Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering alternative or complementary career paths to a traditional MD, online nursing programs offer accessible and flexible options. There is a wide range of online nursing courses that make it easier for aspiring healthcare professionals to start or advance in their careers from anywhere.

For registered nurses seeking career growth, cheap rn to bsn online programs are a popular choice. These affordable pathway programs allow nurses to earn a bachelor’s degree while continuing to work, making advancement accessible and cost-effective.

Individuals with a non-nursing bachelor’s degree can pursue leadership roles in healthcare through non nursing bachelor's to msn online programs. These direct-entry options are designed for career changers who want to quickly transition into advanced nursing positions.

For those committed to research or academia, online nursing phd programs provide a pathway to the highest qualifications in nursing. These flexible doctoral programs support working professionals who aim to specialize in leadership or research within healthcare.

Best Scientists Citing Carle Paul

Trending Scientists

Recently Published Articles